New Therapy Option for Teenagers with Chronic Rhinosinusitis

  • Regeneron and Sanofi receive FDA approval for Dupixent treatment
  • Treatment approved for adolescents with inadequately controlled chronic rhinosinusitis with nasal polyps
  • Expands on initial clearance from June 2019 for adult use
  • Significant improvements seen in clinical trials compared to placebo
  • Over one million patients already using Dupixent globally

Regeneron Pharmaceuticals and Sanofi have received FDA approval for their treatment of an inflammatory condition affecting sinuses and nasal passages in adolescents. Dupixent, the treatment, is now an add-on maintenance therapy for patients aged 12 to 17 with inadequately controlled chronic rhinosinusitis with nasal polyps. Previously, standard treatments were systemic steroids or surgery. This approval builds on Dupixent’s initial clearance from June 2019 for adult use. Clinical trials in adults showed significant improvements at 24 weeks compared to placebo and are supported by safety data in adolescents aged 12 and up with moderate-to-severe asthma. Regeneron President George Yancopoulos said over one million patients worldwide are currently using Dupixent.

Factuality Level: 10
Factuality Justification: The article provides accurate information about the FDA approval for Dupixent as a treatment for adolescents with chronic rhinosinusitis with nasal polyps and mentions its previous approval for adults. It also includes quotes from Regeneron President George Yancopoulos that support the benefits of the treatment.
Noise Level: 3
Noise Justification: The article provides relevant information about the FDA approval of Dupixent for a specific medical condition in adolescents and mentions its benefits compared to previous treatments. It also includes quotes from Regeneron’s President. However, it could provide more context on the disease and the impact of the treatment on patients’ lives or compare it with other available treatments.
Public Companies: Regeneron Pharmaceuticals (REGN), Sanofi (SNY)
Key People: George Yancopoulos (President and Science Chief)

Track all markets on TradingView

Financial Relevance: Yes
Financial Markets Impacted: Sanofi and Regeneron Pharmaceuticals stocks
Financial Rating Justification: The approval of Dupixent for a new patient population expands the potential market for this treatment, which could impact the financial performance of both companies.
Presence Of Extreme Event: No
Nature Of Extreme Event: Other
Impact Rating Of The Extreme Event: No
Extreme Rating Justification: There is no extreme event mentioned in the article.
Move Size: No market move size mentioned.
Sector: Healthcare
Direction: Up
Magnitude: Medium
Affected Instruments: Stocks

Reported publicly: www.marketwatch.com